Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Korro (Nasdaq: KRRO) will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 10:30 a.m. PT / 1:30 p.m. ET. Ram Aiyar, Ph.D., CEO and President, will deliver the presentation; Todd Chappell, COO, and Loic Vincent, Ph.D., CSO, will also participate.
A live webcast will be available on Korro's Events & Presentations investor page at www.korrobio.com, and a replay will be accessible for 30 days following the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – KRRO
On the day this news was published, KRRO gained 7.77%, reflecting a notable positive market reaction. Argus tracked a peak move of +2.6% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $6M to the company's valuation, bringing the market cap to $87M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
KRRO gained 2.78% while key biotech peers showed mixed single-digit moves (e.g., FDMT +6.58%, IMRX +22.14%), pointing to a stock-specific reaction rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 12 | Earnings & pipeline | Negative | -4.2% | Q3 2025 results, KRRO-110 underperformance and workforce reduction details. |
| Sep 02 | Conference participation | Positive | +17.3% | Announcement of participation in multiple investor and scientific conferences. |
| Aug 12 | Earnings & trial update | Positive | +6.3% | Q2 2025 results and progress in Phase 1/2a REWRITE trial for KRRO-110. |
| Jul 21 | Regulatory designation | Positive | -2.4% | EMA orphan drug designation for KRRO-110 in AATD. |
KRRO has generally reacted positively to earnings and conference participation, with one notable negative reaction to mixed clinical and restructuring updates.
Over recent months, KRRO’s news flow has centered on clinical progress, restructuring, and investor outreach. Q2 and Q3 2025 earnings updates highlighted KRRO-110 clinical data, cash balances of $119.6M and $102.5M, and a workforce reduction of 34%, with share reactions of +6.25% and -4.21%. A September 2025 conference slate produced a strong +17.25% move, while an EMA orphan designation in July 2025 saw a modest decline. Today’s J.P. Morgan conference appearance fits into this pattern of active investor and scientific engagement.
Market Pulse Summary
The stock moved +7.8% in the session following this news. A strong positive reaction aligns with KRRO’s history of notable moves around conference participation and investor outreach. Past events like the September 2025 conference slate saw a +17.25% move, suggesting investors have responded to increased visibility. However, prior mixed updates on KRRO-110 and recent restructuring showed that sentiment can shift quickly, so traders would have weighed execution risk, clinical progress, and balance-sheet disclosures from recent earnings when judging durability of the gains.
AI-generated analysis. Not financial advice.
CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 10:30 a.m. PT (1:30 p.m. ET). Todd Chappell, Chief Operating Officer, and Loic Vincent, Ph.D., Chief Scientific Officer, will also be participating at the conference.
A live webcast of the presentation can be accessed on the “Events & Presentations” page in the Investor section of Korro’s website at www.korrobio.com. Following the presentation, a replay of the event will be available for 30 days.
About Korro
Korro is a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, enabling a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.
Korro intends to use its Investor Relations website, LinkedIn, and X (Twitter) as means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Korro’s Investor Relations website and follow @KorroBio on LinkedIn, and X (Twitter), in addition to following Korro’s press releases, SEC filings, public conference calls, presentations, and webcasts.
Korro Bio Contact Information
Investor & Media Contact
IR@korrobio.com
FAQ
When will Korro (KRRO) present at the J.P. Morgan Healthcare Conference?
Who from Korro (KRRO) will present at the January 15, 2026 conference?
How can investors watch Korro's (KRRO) J.P. Morgan presentation on January 15, 2026?
Will there be a replay of Korro's (KRRO) J.P. Morgan presentation and for how long?
What time is Korro's (KRRO) presentation in Eastern Time on January 15, 2026?
